Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [7] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [7] Industry Context - The biotechnology sector is currently experiencing a bear market, with approximately 25% of the 700 to 800 publicly traded US biotech companies having negative enterprise values [3] - The upcoming webinar event titled "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" aims to discuss investment opportunities in this challenging environment [2][3] Event Details - Serina's CEO, Steven A. Ledger, will present at the Tribe Public's Webinar on June 11, 2025, at 8:30 am Pacific / 11:30 am Eastern [2] - Participants can submit questions for the CEO before and during the event, which will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr. [6]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform for drug optimization [5]. Leadership Appointment - Dr. Stephen Brannan has been appointed to the Board of Directors, bringing over 30 years of experience in neuroscience and neuropsychiatry drug development [2][3]. - Dr. Brannan previously served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical strategy for KarXT, a groundbreaking therapy for schizophrenia that contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024 [2][3]. Strategic Focus - The company aims to advance long-acting treatments for movement disorders and other CNS conditions, aligning with Dr. Brannan's expertise in designing data-driven clinical trials and understanding patient and commercial needs [3]. Previous Experience - Dr. Brannan has held senior roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, directing clinical development programs in various CNS conditions [3]. - He is a founding member of the CNS Summit Leadership Council and has served on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM) [3]. Board Changes - Remy Gross has departed from the Board of Directors, with the company expressing gratitude for his contributions during its transition from a private to a public entity [5].

Core Insights - Serina Therapeutics is making significant progress in developing its proprietary POZ Platform for drug optimization, particularly focusing on SER-252 for advanced Parkinson's care [2][3] - The company has secured $15 million in equity financing, enhancing its financial foundation to support ongoing clinical trials and research initiatives [7] - Recent data presented at a summit indicates that Serina's POZ-lipid technology may lead to safer and more effective lipid nanoparticle formulations for gene therapy [7] Recent Highlights - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 by Q4 2025 [6] - Two experienced biotech leaders have been added to the Board of Directors, enhancing corporate strategy and business development capabilities [7] - The POZ Platform is being advanced across multiple therapeutic modalities, including neurological disorders and RNA-based therapeutics [2][7] First Quarter Operating Results - Revenues for Q1 2025 were not material, similar to Q1 2024 [4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, driven by higher R&D and administrative costs [4][6] - R&D expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, primarily due to increased headcount and professional fees [5] Financial Performance - The net loss for Q1 2025 was $4.8 million, or $(0.49) per share, compared to a net loss of $15.0 million, or $(5.38) per share, in Q1 2024 [10][22] - Other income for Q1 2025 was $1.0 million, a significant improvement from a net expense of $12.7 million in Q1 2024 [9][22] - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025 [11] Liquidity Information - The company has a strengthened balance sheet following recent financing, which includes a $10 million investment from JuvVentures and a $5 million private placement [7][11] - Total current assets as of March 31, 2025, were $5.8 million, with total liabilities at $5.2 million [20][21]

Financial Performance - Revenues for the first quarter of 2025 were not material, remaining at $0 compared to $5,000 in the same period of 2024[4] - Operating expenses increased to $5.9 million in Q1 2025 from $2.3 million in Q1 2024, representing a 155% increase[4] - Research and development expenses rose to $3.0 million in Q1 2025, up from $1.1 million in Q1 2024, marking a 173% increase[5] - General and administrative expenses were $2.9 million in Q1 2025, compared to $1.2 million in Q1 2024, reflecting a 142% increase[6] - The net loss attributable to Serina for Q1 2025 was $4.8 million, or $(0.49) per share, significantly improved from a net loss of $15.0 million, or $(5.38) per share, in Q1 2024[10] - Net loss for the three months ended March 31, 2025, was $4.822 million, compared to a net loss of $15.015 million for the same period in 2024[25] Cash Flow and Financing - Cash and cash equivalents totaled $4.3 million as of March 31, 2025, with projections indicating sufficient funds to last through Q3 2025[11] - Serina secured $15 million in equity financing since late 2024, including a $10 million investment from JuvVentures and a $5 million private placement[7] - Net cash used in operating activities increased to $4.322 million from $1.577 million year-over-year[25] - Cash and cash equivalents at the end of the period were $4.267 million, down from $8.756 million at the end of the same period in 2024[25] - Net cash provided by financing activities was $4.917 million, compared to $2.728 million in the previous year[25] - The company drew down on loan facilities from Juvenescence, resulting in no cash outflow reported for the current period[25] Operational Developments - The company is on track to dose the first patient in the Phase 1b clinical trial of SER-252 for advanced Parkinson's disease by Q4 2025[6] - New data presented at a summit showed Serina's POZ-lipid did not trigger an immune response, indicating potential for safer LNP formulations[7] Changes in Financial Position - Other income for Q1 2025 was $1.0 million, a turnaround from a net expense of $12.7 million in Q1 2024, indicating a $13.7 million improvement[9] - Stock-based compensation increased significantly to $956,000 from $53,000 year-over-year[25] - The company reported a change in fair value of convertible promissory notes, which was $0 in the current period compared to $7.017 million in the previous year[25] - The company had a significant increase in accounts payable, which rose to $441,000 from $244,000 year-over-year[25] - The issuance of common stock upon conversion of Preferred Stock was $0 in the current period, compared to $36.404 million in the previous year[25] - The merger and issuance of common stock upon consummation of the merger on March 26, 2024, resulted in $0 in the current period, compared to $961,000 in the previous year[25]

Financial Performance - The company reported an operating loss of $5.9 million for the three months ended March 31, 2025, compared to a loss of $2.3 million for the same period in 2024, reflecting an increase of $3.6 million [117]. - The company reported net losses of $4.8 million for the three months ended March 31, 2025, compared to a net loss of $15.0 million for the same period in 2024, reflecting a decrease of $10.2 million [138]. - Other income net was $1.0 million for the three months ended March 31, 2025, compared to a net expense of $12.7 million in the same period in 2024, resulting in a $13.7 million improvement [141]. - The net loss for the three months ended March 31, 2025, was $4.8 million, compared to a net loss of $15.0 million in the same period in 2024 [152][154]. Expenses - Research and development expenses increased to $3.0 million for the three months ended March 31, 2025, up from $1.1 million in the same period in 2024, representing a $1.9 million increase [139]. - Total operating expenses for the three months ended March 31, 2025, were $5.9 million, compared to $2.3 million for the same period in 2024, indicating a $3.5 million increase [138]. - General and administrative expenses increased to $2.9 million for the three months ended March 31, 2025, from $1.2 million in the same period in 2024, representing a 141.7% increase [140]. - Net cash used in operating activities for the three months ended March 31, 2025, was $4.3 million, a 174.1% increase from $1.6 million in the same period in 2024 [151]. Cash and Financing - Cash and cash equivalents were reported at $4.3 million as of March 31, 2025 [117]. - As of March 31, 2025, the company had $4.3 million in cash and cash equivalents, with significant financing from the issuance of common stock and convertible notes prior to the merger [144]. - Net cash provided by financing activities for the three months ended March 31, 2025, was $4.9 million, an increase of 80.2% from $2.7 million in the same period in 2024 [155][156]. - The company may need to raise additional capital through equity offerings, debt financings, or other arrangements to fund operations for the foreseeable future [149]. Accumulated Deficit and Future Outlook - The company had an accumulated deficit of $49.1 million as of March 31, 2025 [117]. - The accumulated deficit as of March 31, 2025, was $49.1 million, raising substantial doubt about the company's ability to continue as a going concern [146]. - The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development [118]. - The company anticipates that research and development expenses, general and administrative expenses, and capital expenditures will continue to increase [148].

Core Insights - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing its proprietary POZ Platform™ for drug optimization [2] - The company is set to present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT [1] Company Overview - Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] - The company is developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other indications [2] - The POZ Platform™ has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [2]

Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of wholly owned drug product candidates aimed at treating neurological diseases and other indications [2] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] Technology and Innovation - Serina's proprietary POZ Platform is designed to enhance the integrated efficacy and safety profile of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs) [2] Upcoming Events - Steve Ledger, the CEO of Serina, is scheduled to present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT [1] - A live webcast of the presentation will be available for registered attendees, with an archived replay accessible for 90 days post-event [1]

Core Insights - Serina Therapeutics is presenting new data on its POZ-lipid technology at the 4th LNP Formulation & Process Development Summit, focusing on its potential to address challenges related to anti-PEG antibodies in mRNA vaccines [1][2] - The POZ-lipid demonstrated no IgM or IgG antibody response in rats, contrasting with PEG-lipid standards that elicited a strong antibody response, indicating a safer alternative for LNP formulations [2][3] - The absence of an immune response to POZ-lipid could lead to the development of safer and more effective gene therapy and RNA-based medicines, addressing concerns related to anaphylaxis and adverse events from PEGylated vaccines [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform™ for drug optimization [4] - The POZ Platform™ aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates [4]

Core Insights - Serina Therapeutics is presenting new data on its POZ-lipid technology at the 4th LNP Formulation & Process Development Summit, focusing on its potential to address challenges with anti-PEG antibodies in mRNA vaccines [1][2] - The POZ-lipid demonstrated no IgM or IgG antibody response in rats, contrasting with PEG-lipid standards that triggered a strong antibody response [2][3] - The absence of an immune response to POZ-lipid could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines [3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates for neurological diseases and other indications [4] - The company utilizes its proprietary POZ Platform™ to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [4]

Core Insights - Serina Therapeutics, Inc. has successfully closed a $5 million financing round from strategic shareholders to support the development of its lead clinical candidate SER-252 for Advanced Parkinson's disease [1][2] - The company plans to initiate a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025, indicating a strong commitment to advancing its clinical pipeline [1][2] Financing Details - The financing involved the issuance of 965,250 shares of convertible preferred stock at a price of $5.18 per share, which aligns with the closing price of its common stock on April 7, 2025 [2] Product Overview - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [3] - The product utilizes Enable Injections' enFuse™ wearable drug delivery platform, enhancing patient comfort through easy administration via long-acting subcutaneous injection [3] Technology Platform - Serina's proprietary POZ Platform™ is based on a synthetic polymer that allows for better control in drug loading and precision in drug release rates [4] - The POZ technology aims to improve the pharmacokinetic profiles of existing drugs, potentially addressing issues like toxicity and short half-life [4] Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [5] - The company is headquartered in Huntsville, Alabama, and is positioned to leverage its POZ Platform™ across various therapeutic modalities [5]